Nonsmall cell lung cancer (NSCLC) constitutes approximately 80% of all lung cancer, with anaplastic lymphoma kinase (ALK) fusion gene-positive NSCLC accounts for roughly 3% to 7% of cases.[1] Next-generation sequencing (NGS) has identified over 90 ALK-fusion subtypes, with the majority being single variants. This evidence concerns the gene ALK and lung carcinoma.